Home  »  Company   »  BioAtla Inc. (NASDAQ:BCAB) Price Forecast For The ...

BioAtla Inc. (NASDAQ:BCAB) Price Forecast For The Next 12 Months Is Set At $68.00.

In last trading session, BioAtla Inc. (NASDAQ:BCAB) saw 0.39 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $9.51 trading at $0.71 or 8.07% at ring of the bell on the day assigns it a market valuation of $463.90M. That closing price of BCAB’s stock is at a discount of -175.5% from its 52-week high price of $26.20 and is indicating a premium of 78.86% from its 52-week low price of $2.01. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.44 million shares which gives us an average trading volume of 558.51K if we extend that period to 3-months.

For BioAtla Inc. (BCAB), analysts’ consensus is at an average recommendation of a Buy while assigning it a mean rating of 1.90. Splitting up the data highlights that, out of 7 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.8 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

BioAtla Inc. (NASDAQ:BCAB) trade information

Upright in the green during last session for gaining 8.07%, in the last five days BCAB remained trading in the green while hitting it’s week-highest on Wednesday, 11/23/22 when the stock touched $9.51 price level, adding 1.45% to its value on the day. BioAtla Inc.’s shares saw a change of -51.55% in year-to-date performance and have moved 6.49% in past 5-day. BioAtla Inc. (NASDAQ:BCAB) showed a performance of 38.43% in past 30-days. Number of shares sold short was 5.09 million shares which calculate 13.91 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $27.71 to the stock, which implies a rise of 65.68% to its current value. Analysts have been projecting $8.00 as a low price target for the stock while placing it at a high target of $68.00. It follows that stock’s current price would drop -615.04% in reaching the projected high whereas dropping to the targeted low would mean a gain of 15.88% for stock’s current value.

BioAtla Inc. (BCAB) estimates and forecasts

Statistics highlight that BioAtla Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 332.27% of value to its shares in past 6 months, showing an annual growth rate of -6.16% while that of industry is 4.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -17.60% in the current quarter and calculating -21.00% decrease in the next quarter. This year revenue growth is estimated to rise 1,168.00% from the last financial year’s standing.

6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $470k for the same. And 6 analysts are in estimates of company making revenue of $2.7 million in the next quarter that will end on Dec 2022.

BCAB Dividends

BioAtla Inc. is more likely to be releasing its next quarterly report on November 03 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

BioAtla Inc. (NASDAQ:BCAB)’s Major holders

Insiders are in possession of 16.33% of company’s total shares while institution are holding 70.89 percent of that, with stock having share float percentage of 84.72%. Investors also watch the number of corporate investors in a company very closely, which is 70.89% institutions for BioAtla Inc. that are currently holding shares of the company. Tang Capital Management, LLC is the top institutional holder at BCAB for having 3.37 million shares of worth $9.61 million. And as of Jun 29, 2022, it was holding 9.29% of the company’s outstanding shares.

The second largest institutional holder is Soleus Capital Management, L.P., which was holding about 3.26 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 8.99% of outstanding shares, having a total worth of $9.3 million.

On the other hand, Vanguard Total Stock Market Index Fund and Janus Henderson Global Life Sciences Fund are the top two Mutual Funds which own company’s shares. As of Jun 29, 2022, the former fund manager was holding 0.87 million shares of worth $2.47 million or 2.39% of the total outstanding shares. The later fund manager was in possession of 0.5 million shares on Jun 29, 2022, making its stake of worth around $1.43 million in the company or a holder of 1.38% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]